PL2271218T3 - Zastosowanie i kompozycja do leczenie otępienia - Google Patents

Zastosowanie i kompozycja do leczenie otępienia

Info

Publication number
PL2271218T3
PL2271218T3 PL09726036T PL09726036T PL2271218T3 PL 2271218 T3 PL2271218 T3 PL 2271218T3 PL 09726036 T PL09726036 T PL 09726036T PL 09726036 T PL09726036 T PL 09726036T PL 2271218 T3 PL2271218 T3 PL 2271218T3
Authority
PL
Poland
Prior art keywords
composition
treating dementia
dementia
treating
Prior art date
Application number
PL09726036T
Other languages
English (en)
Polish (pl)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2271218(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of PL2271218T3 publication Critical patent/PL2271218T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09726036T 2008-03-27 2009-03-17 Zastosowanie i kompozycja do leczenie otępienia PL2271218T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08005750 2008-03-27
EP09726036.8A EP2271218B1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia
PCT/US2009/001662 WO2009120277A1 (en) 2008-03-27 2009-03-17 Use and composition for treating dementia

Publications (1)

Publication Number Publication Date
PL2271218T3 true PL2271218T3 (pl) 2017-10-31

Family

ID=39535697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09726036T PL2271218T3 (pl) 2008-03-27 2009-03-17 Zastosowanie i kompozycja do leczenie otępienia

Country Status (10)

Country Link
US (5) US8404701B2 (enExample)
EP (3) EP3178477A1 (enExample)
JP (3) JP5647099B2 (enExample)
AU (1) AU2009229372C1 (enExample)
CA (1) CA2718411C (enExample)
DK (1) DK2271218T3 (enExample)
ES (1) ES2634421T3 (enExample)
MX (3) MX2010010460A (enExample)
PL (1) PL2271218T3 (enExample)
WO (1) WO2009120277A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
MX2010010460A (es) * 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
ES2746480T3 (es) 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
JP2011213606A (ja) * 2010-03-31 2011-10-27 Sawai Pharmaceutical Co Ltd ドネペジルを含有する固形製剤の製造方法
JP2011213695A (ja) * 2010-04-02 2011-10-27 Taisho Pharm Ind Ltd ドネペジル塩酸塩含有口腔内速崩壊錠
MX378091B (es) * 2012-09-05 2025-03-10 Chase Pharmaceuticals Corp Composicion neuroprotectora anticolinergica y metodos.
WO2016112263A1 (en) * 2015-01-09 2016-07-14 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US20180050018A1 (en) * 2015-03-06 2018-02-22 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
US10307409B2 (en) * 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
WO2016204998A1 (en) 2015-06-15 2016-12-22 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
US10479706B2 (en) * 2016-06-03 2019-11-19 Katz Water Tech, Llc Apparatus, method and system for desalinating water
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
CN112040936B (zh) * 2018-04-17 2024-07-23 罗曼治疗系统股份公司 用于透皮施用索利那新的透皮治疗系统
CN115581696A (zh) 2018-09-28 2023-01-10 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
WO2022058940A1 (ko) * 2020-09-21 2022-03-24 닥터레이몬드 랩(주) 인지 능력 개선 또는 기억력 증진용 의약 조성물
EP4251608A4 (en) * 2020-11-26 2025-02-12 Rezubio Pharmaceuticals Co., Ltd ANTICHOLINERGIC AGENTS
US12109202B2 (en) 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB795758A (en) 1955-08-22 1958-05-28 Pfizer & Co C Amino esters and the preparation thereof
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (enExample) 1973-07-12 1974-06-20
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4798841A (en) 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US4937239A (en) 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9612710D0 (en) 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
EP0949920B1 (en) 1997-07-09 2005-12-07 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
JP2004529117A (ja) * 2001-02-08 2004-09-24 シェーリング　コーポレイション 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7427280B2 (en) * 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US6974820B2 (en) 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
CN1520818A (zh) 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8299062B2 (en) 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US7399778B2 (en) 2004-01-16 2008-07-15 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
RU2394570C2 (ru) 2004-02-20 2010-07-20 Новартис Аг Ингибиторы dpp-iv для лечения нейродегенерации и когнитивных расстройств
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
BRPI0518396A2 (pt) 2004-12-27 2008-11-18 Eisai R&D Man Co Ltd mÉtodo para estabilizaÇço de droga anti-demÊncia
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070004766A1 (en) 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
WO2007043057A2 (en) 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2008013539A (es) * 2006-04-21 2008-10-29 Wyeth Corp Produccion de intermediarios de amino alcohol quiralmente puros, derivados de los mismos, y usos de los mismos.
MX2009002715A (es) * 2006-09-12 2009-08-12 Adolor Corp Metodos para mejorar la funcion cognoscitiva.
US20080090808A1 (en) 2006-10-17 2008-04-17 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US8097633B2 (en) * 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
MX2010010460A (es) * 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
ES2746480T3 (es) * 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer

Also Published As

Publication number Publication date
MX344177B (es) 2016-12-08
EP2271218B1 (en) 2017-05-24
US9044472B2 (en) 2015-06-02
US20190091214A1 (en) 2019-03-28
JP2014114295A (ja) 2014-06-26
JP5647099B2 (ja) 2014-12-24
JP2011518776A (ja) 2011-06-30
US20110021503A1 (en) 2011-01-27
US20140275036A1 (en) 2014-09-18
JP2016179980A (ja) 2016-10-13
CA2718411C (en) 2016-02-16
AU2009229372C1 (en) 2017-02-02
EP4088717A1 (en) 2022-11-16
EP3178477A1 (en) 2017-06-14
CA2718411A1 (en) 2009-10-01
AU2009229372A1 (en) 2009-10-01
US20130158012A1 (en) 2013-06-20
AU2009229372B2 (en) 2014-09-25
MX2010010460A (es) 2010-12-15
DK2271218T3 (en) 2017-09-11
EP2271218A4 (en) 2011-05-18
EP2271218A1 (en) 2011-01-12
WO2009120277A1 (en) 2009-10-01
JP6427522B2 (ja) 2018-11-21
MX347901B (es) 2017-05-18
US8404701B2 (en) 2013-03-26
US20150224096A1 (en) 2015-08-13
ES2634421T3 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
PL2271218T3 (pl) Zastosowanie i kompozycja do leczenie otępienia
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
IL202015A0 (en) Methods and compositions for treating skin conditions
SI2245037T1 (sl) Nove spojine in postopki za zdravljenje
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2259796A4 (en) MATERIALS AND METHODS FOR IMPROVED IMMUNE LYCOPROTEINS
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2355660A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
EP2291284A4 (en) COMPOSITIONS FOR TREATING MATERIALS AND TREATMENT METHOD THEREFOR
EP2512504A4 (en) COMPOSITION AND THERAPEUTIC METHOD
ZA201006657B (en) Disinfection composition and process
ZA201009066B (en) Materials and methods for suppressing and/or treating neurofibroma and related tumors
GB0801319D0 (en) Compounds and their use
AP2829A (en) Disinfection composition and process
GB2461611B (en) Composition and use thereof
GB0714500D0 (en) composition and treatment
GB0807102D0 (en) Process and composition
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0807336D0 (en) Composition and process
GB0806334D0 (en) Method and composition
GB0817553D0 (en) Composition and method